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Abstract
RNA interference (RNAi) is a powerful strategy for studying the phenotypic consequences of reduced gene expression levels
in model systems. To develop a method for the rapid characterization of the developmental consequences of gene
dysregulation, we tested the use of RNAi for ‘‘transient transgenic’’ knockdown of mRNA in mouse embryos. These methods
included lentiviral infection as well as transposition using the Sleeping Beauty (SB) and PiggyBac (PB) transposable element
systems. This approach can be useful for phenotypic validation of putative mutant loci, as we demonstrate by confirming
that knockdown of Prdm16 phenocopies the ENU-induced cleft palate (CP) mutant, csp1. This strategy is attractive as an
alternative to gene targeting in embryonic stem cells, as it is simple and yields phenotypic information in a matter of weeks.
Of the three methodologies tested, the PB transposon system produced high numbers of transgenic embryos with the
expected phenotype, demonstrating its utility as a screening method.
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Introduction
The production of targeted mutations in mice remains the gold
standard for the analysis of the loss-of-function studies of specific
genes in mammals. However, even with the emergence of large-
scale knockout mouse resources, such as those of the International
Knockout Mouse Consortium (http://www.knockoutmouse.org/),
generation of such mutants using embryonic stem (ES) cells may
still require substantial time and resources. In particular, this
approach is difficult to pursue for high throughput applications.
For instance, linkage and association studies for mutations or
strain-specific traits may yield a large number of positional
candidate genes, which may require testing individually to assess
causality. Similarly, microarray analyses typically result in lists of
differentially expressed genes, with little indication regarding
which ones may be key regulators. An efficient methodology to
rapidly screen genes in vivo would enhance the functional analysis
of outputs from high throughput screening.
The discovery of RNA interference (RNAi) and its application
in mammals has provided a new avenue to study the consequences
of reduced gene expression [1,2]. In this process, short 19–25 nt
double-stranded RNA (dsRNA) duplexes mediate the degradation
of mRNA transcripts that contain an exact match to the dsRNA
sequence (reviewed in [3]). This occurs through the recruitment of
the RNase III enzyme, Dicer, followed by a multicomponent
nuclease complex known as RISC (RNA-induced silencing
complex). Alternatively, mismatched dsRNAs can lead to reduced
gene activity through the suppression of protein translation [4].
Current methods for the utilization of RNAi as a means to test
the effect of loss of gene function involve direct introduction of
short interfering RNAs (siRNAs) or expression of precursor short
hairpin RNAs (shRNAs) expressed on plasmids and retroviruses
[2,5,6]. shRNA-expressing vector systems, including lentivirus and
transposable elements vectors, provide highly efficient, stable
shRNA expression in cultured cells and transgenic mammals
(reviewed in [7,8]). Lentiviral infection of ES cells, morula, or
single-cell embryos (via injection into the perivitelline space) has
been successfully employed for transgenesis in mice and
subsequent RNAi knockdown [9,10]. However, these protocols
are not routinely employed in microinjection facilities. In contrast,
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14375the Sleeping Beauty (SB) and PiggyBac (PB) transposon systems can be
employed using standard microinjection protocols that yield
substantially higher transgenic efficiency than traditional pronu-
clear DNA injections [7,11,12,13 and this study]. These
transposon systems have two-components, the first of which is a
transposon vector containing an expression cassette flanked by
terminal inverted repeats that have binding sites for the SB or PB
transposase in direct orientation, termed IR/DRs. The second
component is SB or PB transposase mRNA, which can be co-
expressed from a plasmid or transcribed in vitro. The specific
transposase mediates transposition via a ‘‘cut and paste’’
mechanism in which the transposable element is excised from a
donor plasmid, followed by its integration into the host genome at
a specific target DNA sequence: TA for SB; TTAA for PB. SB
transposons have recently been used in combination with RNAi to
achieve stable reduction of gene expression in cultured cells [14].
One of several potential applications of a rapid method for
RNAi knockdown in embryos is the validation of N-ethyl-N-
nitrosourea (ENU)-induced mutations. ENU screens performed in
mice have successfully identified a wide spectrum of abnormal
phenotypes affecting development [15,16,17,18]. The mutations
induced by ENU can affect non-coding regulatory sequences and
will not be discovered by the usual exon-directed sequencing
analysis. In addition, it is possible that multiple ENU-induced
mutations are present within the genetically defined recombinant
interval carrying the causal locus. Therefore, even when a putative
mutation is identified, independent validation of the positionally-
cloned gene mutation is desirable. We explored whether RNAi
could be efficiently used for targeted mutagenesis by employing a
‘‘transient transgenic’’ protocol; i.e., transgenic analysis in which
microinjected embryos are not used to generate stable lines, but
rather examined directly. Similar approaches to assay loss of gene
function have been used successfully in zebrafish [19,20].
We have previously identified the cleft secondary palate 1 (csp1)
mutant in an ENU mutagenesis screen for recessive late-term
developmental anomalies that model human birth defects [15].
Newborn homozygous csp1 mutant pups on an FVB/NJ strain
background exhibit cleft secondary palate with virtually complete
penetrance and die within 24 hours (Fig. 1A and B). Positional
cloning revealed that this mutant carries an intronic splicing
mutation in the Prdm16 zinc finger transcription factor gene on
distal chromosome 4. We have since confirmed the etiology of the
csp1 mutation in Prdm16 by carrying out a complementation test
with a Prdm16 gene trap mutation [21].
In this study, we utilized several variants of lentivirus and SB
and PB transposons to express Prdm16-specific shRNAs and
compared their efficacy for transgenesis and phenotypic validation
of the mutant allele. RNAi knockdown of Prdm16 using each
system successfully recapitulated the csp1 CP phenotype in
transient transgenic mouse embryos. Lentiviral infection yielded
high transgenic efficiency with modest phenotypic penetrance. SB
transposon-mediated transgenesis resulted in low transgenic
efficiency with high phenotypic penetrance. However, nonviral
PB transposon-mediated transgenesis yielded both high transgenic
efficiency and high phenotypic penetrance. As this system is
amenable for use in any laboratory and transgenic facility, it
Figure 1. The recessive ENU-induced csp1 mutation in Prdm16 exhibits cleft secondary palate. Homozygous csp1 mutants are born with
cleft palate (CP) and die within 24 hours after birth (A–D). Bouin’s fixed wild type (A) and csp1 (B) mutant newborn pups with CP (A and B). The
unaffected primary palates (black arrowheads) and fused or cleft secondary palate are evident (open arrowheads in A and B, respectively).
Hematoxylin and Eosin-stained coronal sections through wild-type (C) and csp1 mutant (D) embryonic day (E) 15.5 embryos show impaired palate
shelf elevation in mutants. Tongue, T; palate shelf, ps; Meckel’s cartilage, mc and molar, m.
doi:10.1371/journal.pone.0014375.g001
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PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14375represents an ideal means for the rapid analysis of the
consequences of mRNA knockdown in a mammalian system.
Results
In mice, secondary palate development begins with palate shelf
outgrowth from the maxillary prominences at E12.5, followed by
downward growth along either side of the tongue and then
concurrent rapid shelf elevation and flattening of the tongue at
approximately E14. Fusion occurs between the medial edge
epithelium (MEE) of the two palate shelves through a combination
of epithelial-mesenchymal transformation, cell migration and
apoptosis [22,23]. Apposition and fusion of the palatal shelves at
the midline occurs by E14.5 in most mouse strains. We initiated
transient transgenic RNAi experiments in mice to examine the
effect of reduced Prdm16 expression in E16.5 mouse embryos, by
which time wild type palate shelves have elevated and fused [23].
Selection of efficient Prdm16-specific shRNAs for RNAi
Prdm16 is comprised of 17 exons, and the Prdm16 transcript is
4394 nucleotides and contains an open reading frame that encodes
a 1277 amino acid protein (Fig. 2A, NM_027504) [24]. To identify
a sequence that would mediate effective RNAi, we selected eight
Prdm16-specific siRNA sequences that meet eight criteria previ-
ously associated with efficient siRNA knockdown (Table 1, Fig. 2A)
[25]. We utilized sense and antisense shRNA oligonucleotides
comprised of the sense siRNA target sequence, a stem loop
sequence, the antisense siRNA target sequence, a 5-thymidine
terminator sequence and appropriate overhangs for cloning
(Table 1) [10]. Annealed sense and antisense shRNA oligonucle-
otides were ligated downstream of the human U6 small nuclear
RNA polymerase III promoter in the lentiviral vector, pLenti-
Lox3.7 (pLL3.7; Fig. 3B), which also contains a CMV-eGFP
expression cassette for visualization of infected cells [10].
We used a luciferase reporter system to assay the effectiveness of
the shRNAs. The coding sequence for a splice variant of Prdm16 in
which exon 16 is absent was subcloned into the 39 UTR of the
luciferase gene contained on a modified pGL3 Firefly luciferase
reporter plasmid (pGL3-DEST-Prdm16) [26]. To measure knock-
down efficiency, luciferase activity was measured after co-
transfection into 293T cells of each shRNA-expressing lentivirus
plasmid with pGL3-DEST-Prdm16 and normalized to the activity
obtained from a co-transfected pRL-TK Renilla luciferase plasmid.
All shRNA lentiviral plasmids showed knockdown activity, except
for pBB36 (nt 3610), which is in the exon that is not included in
the pGL3-DEST-Prdm16 reporter plasmid (Fig. 2B). pBB30 (nt
622) and pBB31 (nt 1266) facilitated the strongest knockdown, to
approximately 20% of wild-type expression levels. Transfection of
Figure 2. Prdm16-specific shRNA selection and validation of RNAi knock down efficiency. Schematic of Prdm16 mRNA and protein
structure (A). Vertical black lines demarcate exon boundaries. Conserved functional domains include a Positive Regulatory (PR) domain, two multi-
fingered zinc finger DNA binding domains (DBD-1 and DBD-2), repressor domain (RD), acidic domain (AD) and Proline-rich region (PRR). Eight
Prdm16-specific shRNAs are shown with respect to their positions within the Prdm16 coding sequence (green diamonds). The red inverted ‘‘V’’ depicts
the alternatively spliced exon 16. Prdm16 mRNA knock down efficiency in vitro mediated by expression of the candidate shRNAs from pLL3.7
lentivirus plasmids or CpG-free Sleeping Beauty (SB) transposons measured by relative luciferase activity (B). RNAi knock down values for effector
shRNAs were normalized against the knockdown efficiency of an empty plasmid control transfection, and transfection efficiencies were calculated
based upon the co-transfection of a Renilla luciferase control expression plasmid. Transfections were performed in duplicate for screening purposes,
and error bars show the standard deviations.
doi:10.1371/journal.pone.0014375.g002
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PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14375T
a
b
l
e
1
.
P
r
d
m
1
6
-
s
p
e
c
i
f
i
c
s
h
R
N
A
e
x
p
r
e
s
s
i
o
n
p
l
a
s
m
i
d
s
e
q
u
e
n
c
e
s
.
P
l
a
s
m
i
d
#
N
a
m
e
P
l
a
s
m
i
d
b
a
c
k
b
o
n
e
P
o
s
i
t
i
o
n
o
f
s
i
R
N
A
i
n
c
d
s
S
e
q
u
e
n
c
e
(
5
9
-
3
9
)
3
0
n
t
6
2
2
p
L
L
3
.
7
6
8
4
–
7
0
2
F
:
T
G
T
T
G
G
T
G
C
A
T
G
T
G
A
A
A
G
A
A
T
T
C
A
A
G
A
G
A
T
T
C
T
T
T
C
A
C
A
T
G
C
A
C
C
A
A
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
T
T
G
G
T
G
C
A
T
G
T
G
A
A
A
G
A
A
T
C
T
C
T
T
G
A
A
T
T
C
T
T
T
C
A
C
A
T
G
C
A
C
C
A
A
C
A
3
1
n
t
1
2
6
6
p
L
L
3
.
7
1
3
2
8
–
1
3
4
6
F
:
T
G
G
A
C
G
C
A
G
A
T
C
A
A
G
T
G
C
A
A
T
T
C
A
A
G
A
G
A
T
T
G
C
A
C
T
T
G
A
T
C
T
G
C
G
T
C
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
G
A
C
G
C
A
G
A
T
C
A
A
G
T
G
C
A
A
T
C
T
C
T
T
G
A
A
T
T
G
C
A
C
T
T
G
A
T
C
T
G
C
G
T
C
C
A
3
2
n
t
1
3
4
3
p
L
L
3
.
7
1
4
0
5
–
1
4
2
3
F
:
T
G
A
G
G
G
C
A
A
G
A
A
C
C
A
T
T
A
C
A
T
T
C
A
A
G
A
G
A
T
G
T
A
A
T
G
G
T
T
C
T
T
G
C
C
C
T
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
A
G
G
G
C
A
A
G
A
A
C
C
A
T
T
A
C
A
T
C
T
C
T
T
G
A
A
T
G
T
A
A
T
G
G
T
T
C
T
T
G
C
C
C
T
C
A
3
3
n
t
1
8
9
4
p
L
L
3
.
7
1
9
5
6
–
1
9
7
4
F
:
T
G
G
A
C
A
G
T
G
A
C
A
G
A
G
A
C
A
A
A
T
T
C
A
A
G
A
G
A
T
T
T
G
T
C
T
C
T
G
T
C
A
C
T
G
T
C
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
G
A
C
A
G
T
G
A
C
A
G
A
G
A
C
A
A
A
T
C
T
C
T
T
G
A
A
T
T
T
G
T
C
T
C
T
G
T
C
A
C
T
G
T
C
C
A
3
4
n
t
2
5
6
6
p
L
L
3
.
7
2
6
2
8
–
2
6
4
6
F
:
T
G
C
A
T
T
A
T
G
C
T
A
A
G
C
C
T
T
C
A
T
T
C
A
A
G
A
G
A
T
G
A
A
G
G
C
T
T
A
G
C
A
T
A
A
T
G
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
C
A
T
T
A
T
G
C
T
A
A
G
C
C
T
T
C
A
T
C
T
C
T
T
G
A
A
T
G
A
A
G
G
C
T
T
A
G
C
A
T
A
A
T
G
C
A
3
5
n
t
3
0
0
0
p
L
L
3
.
7
3
0
6
5
–
3
0
8
3
F
:
T
G
G
A
A
C
A
T
C
C
A
C
A
A
C
A
A
A
G
A
T
T
C
A
A
G
A
G
A
T
C
T
T
T
G
T
T
G
T
G
G
A
T
G
T
T
C
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
G
A
A
C
A
T
C
C
A
C
A
A
C
A
A
A
G
A
T
C
T
C
T
T
G
A
A
T
C
T
T
T
G
T
T
G
T
G
G
A
T
G
T
T
C
C
A
3
6
n
t
3
6
1
0
p
L
L
3
.
7
3
6
7
5
–
3
6
9
3
F
:
T
G
G
A
A
G
C
A
T
T
T
G
A
A
G
T
T
A
A
A
T
T
C
A
A
G
A
G
A
T
T
T
A
A
C
T
T
C
A
A
A
T
G
C
T
T
C
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
G
A
A
G
C
A
T
T
T
G
A
A
G
T
T
A
A
A
T
C
T
C
T
T
G
A
A
T
T
T
A
A
C
T
T
C
A
A
A
T
G
C
T
T
C
C
A
3
7
n
t
3
7
6
4
p
L
L
3
.
7
3
8
2
9
–
3
8
4
7
F
:
T
G
A
T
G
C
T
T
G
G
T
T
G
A
A
C
A
T
C
A
T
T
C
A
A
G
A
G
A
T
G
A
T
G
T
T
C
A
A
C
C
A
A
G
C
A
T
C
T
T
T
T
T
T
C
R
:
T
C
G
A
G
A
A
A
A
A
A
G
A
T
G
C
T
T
G
G
T
T
G
A
A
C
A
T
C
A
T
C
T
C
T
T
G
A
A
T
G
A
T
G
T
T
C
A
A
C
C
A
A
G
C
A
T
C
A
1
1
1
n
t
1
8
9
4
p
K
T
2
-
H
F
(
S
B
)
1
9
5
6
–
1
9
7
4
F
:
A
C
C
T
C
G
G
A
C
A
G
T
G
A
C
A
G
A
G
A
C
A
A
A
T
T
C
A
A
G
A
G
A
T
T
T
G
T
C
T
C
T
G
T
C
A
C
T
G
T
C
C
T
T
T
T
T
T
T
T
R
:
C
A
A
A
A
A
A
A
A
A
A
A
G
G
A
C
A
G
T
G
A
C
A
G
A
G
A
C
A
A
A
T
C
T
C
T
T
G
A
A
T
T
T
G
T
C
T
C
T
G
T
C
A
C
T
G
T
C
C
G
1
1
3
n
t
6
2
2
p
K
T
2
-
H
F
(
S
B
)
6
8
4
–
7
0
2
F
:
A
C
C
T
C
G
T
T
G
G
T
G
C
A
T
G
T
G
A
A
A
G
A
A
T
T
C
A
A
G
A
G
A
T
T
C
T
T
T
C
A
C
A
T
G
C
A
C
C
A
A
C
T
T
T
T
T
T
T
T
R
:
C
A
A
A
A
A
A
A
A
A
A
A
G
T
T
G
G
T
G
C
A
T
G
T
G
A
A
A
G
A
A
T
C
T
C
T
T
G
A
A
T
T
C
T
T
T
C
A
C
A
T
G
C
A
C
C
A
A
C
G
1
1
4
n
t
6
2
2
-
s
c
r
a
m
b
l
e
d
p
K
T
2
-
H
F
(
S
B
)
N
A
F
:
A
C
C
T
C
G
C
G
G
A
G
A
A
A
G
T
G
G
A
T
T
T
A
T
T
T
C
A
A
G
A
G
A
A
T
A
A
A
T
C
C
A
C
T
T
T
C
T
C
C
G
C
T
T
T
T
T
T
T
T
R
:
C
A
A
A
A
A
A
A
A
A
A
A
G
C
G
G
A
G
A
A
A
G
T
G
G
A
T
T
T
A
T
T
C
T
C
T
T
G
A
A
A
T
A
A
A
T
C
C
A
C
T
T
T
C
T
C
C
G
C
G
1
6
0
E
m
p
t
y
U
6
-
n
o
s
h
R
N
A
;
C
M
V
-
e
G
F
P
p
K
T
2
-
H
F
(
S
B
)
N
A
N
o
n
e
1
6
1
U
6
-
n
t
1
2
6
6
s
h
R
N
A
;
C
M
V
-
e
G
F
P
p
K
T
2
-
H
F
(
S
B
)
1
3
2
8
–
1
3
4
6
S
a
m
e
a
s
p
B
B
3
1
1
6
2
U
6
-
n
t
1
8
9
4
s
h
R
N
A
;
C
M
V
-
e
G
F
P
p
K
T
2
-
H
F
(
S
B
)
1
9
5
6
–
1
9
7
4
S
a
m
e
a
s
p
B
B
3
3
1
8
1
E
m
p
t
y
U
6
-
n
o
s
h
R
N
A
p
K
T
2
-
H
F
(
S
B
)
N
A
N
o
n
e
1
8
2
U
6
-
n
t
1
2
6
6
s
h
R
N
A
p
K
T
2
-
H
F
(
S
B
)
1
3
2
8
–
1
3
4
6
S
a
m
e
a
s
p
B
B
3
1
1
8
3
U
6
-
n
t
1
8
9
4
s
h
R
N
A
p
K
T
2
-
H
F
(
S
B
)
1
9
5
6
–
1
9
7
4
S
a
m
e
a
s
p
B
B
3
3
2
0
5
U
6
-
n
t
6
2
2
s
h
R
N
A
p
C
y
L
5
0
(
P
B
)
6
8
4
–
7
0
2
S
a
m
e
a
s
p
B
B
3
0
U
n
d
e
r
l
i
n
e
d
n
u
c
l
e
o
t
i
d
e
s
i
n
e
a
c
h
o
l
i
g
o
n
u
c
l
e
o
t
i
d
e
s
e
q
u
e
n
c
e
r
e
p
r
e
s
e
n
t
t
h
e
s
e
n
s
e
a
n
d
a
n
t
i
s
e
n
s
e
s
e
q
u
e
n
c
e
-
s
p
e
c
i
f
i
c
s
i
R
N
A
t
a
r
g
e
t
s
e
q
u
e
n
c
e
w
i
t
h
i
n
P
r
d
m
1
6
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
1
4
3
7
5
.
t
0
0
1
Transient Transgenic RNAi
PLoS ONE | www.plosone.org 4 December 2010 | Volume 5 | Issue 12 | e14375Prdm16-specific shRNA-expressing SB transposon plasmids
(pBB111, nt1894; pBB115, nt3000) also facilitated strong knock-
down activity in this assay (Fig. 2B).
Lentivirus and Sleeping Beauty/PiggyBac transposons
expressing Prdm16-specific shRNAs recapitulate the csp1
mutant CP phenotype in transient transgenic mouse
embryos
To assay the developmental consequences of RNAi knockdown
of Prdm16 in mice, we performed ‘‘transient’’ transgenic analysis in
which Prdm16-specific shRNAs were introduced into mouse
embryos and litters were examined at E16.5 for the presence of
CP and co-expression of GFP (Fig. 3A). We utilized lentivirus and
SB or PB transposons (Fig. 3B-E) and assayed variables including
shRNA knockdown efficiency, transgene delivery vehicle, trans-
poson methylation status and size and presence or absence of the
GFP reporter. For plasmid DNA injection and lentiviral infection,
we used the pBB30, pBB33 and empty pLL3.7 plasmids described
above. For SB transposon-mediated delivery of Prdm16-specific
shRNAs, methylated or unmethylated transposon DNA and in
vitro-transcribed 59capped Sleeping Beauty transposase (SB11) mRNA
[27] was injected into single cell embryos [11,12]. Similarly, a PB
transposon expressing a Prdm16-specific shRNA was co-injected
with 59-capped PiggyBac transposase (PBase) mRNA. A summary
of all transient transgenic RNAi experiments is provided in
Table 2.
To begin we used traditional transgenic methodologies for
injection of pLL3.7, pBB30 and pBB33 plasmid DNA into single
FVB/J mouse cells (Table 2). Control pLL3.7 injections yielded
Figure 3. Strategy for gene mutation validation and candidate gene screening using transient transgenic RNAi knockdown. Flow
chart outlining the experimental method and the classes of transgenic delivery vehicles and their variants (A). Creation of various shRNA-expressing
lentivirus and Sleeping Beauty (SB) and PiggyBac (PB) transposon plasmids (B–E). B) pLL3.7 lentivirus plasmid was described previously and contains a
U6–shRNA; CMV-eGFP expression cassette [10]. SIN-LTR, self-inactivating long terminal repeat; Y, HIV packaging signal; cPPT, central polypurine track;
MCS, multiple cloning site; CMV, cytomegalovirus promoter; WRE, woodchuck hepatitis virus response element. Sense and antisense sequences that
form the stem of the stem loop shRNA sequence are shown by the solid blue arrows; the loop sequence, green bar and the terminator, red bar. C)
CpG-free EF1-GFP; H1-shRNA SB transposons. IR/DR, inverted/direct terminal repeats recognized by SB transposase; mCMVenh, mouse
cytomegalovirus enhancer sequence; hEF1, human EF1 promoter; eGFP, synthetic GFP coding sequence; H1, human pol III promoter; a-pep, lacZ
alpha peptide for blue-white selection. D) CpG-containing U6-shRNA; CMV-eGFP from pLL3.7 in the SB transposon. E) U6-shRNA expression cassette
from pLL3.7 in the SB and PB transposons. CpG dinucleotides methylated by SssI methylase (red dots) in SB transposon experiments are shown.
doi:10.1371/journal.pone.0014375.g003
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expression (Fig. 4A), but pBB30 and pBB33 yielded substantially
less transgenic embryos and none with CP. To produce
transgenic embryos with increased frequency, we first performed
transient transgenic experiments by lentiviral infection. High
titer (,0.5–1.0610
9 ifu/ml) lentivirus derived from pBB30 was
injected into the perivitelline space of single FVB/NJ mouse
oocytes (Table 2). Transgenic efficiency was 47% (26/55), but
GFPexpressionwasvisibleinonly7%(4/55)ofembryos(Fig.4B).
16% (4/26) of transgenic embryos exhibited CP (Fig. 4D
compared to wild type embryo in Fig. 4C), with an additional
embryo arresting prior to palatogenesis. One CP embryo was not
transgenic by PCR genotyping. Lentiviral transgenesis proved to
be an efficient strategy to validate the csp1 mouse mutation, but
the specialized training, certification and facilities required for
lentivirus experiments, as well as the non-trivial task of isolating
Table 2. Combined summary of transgenic RNAi injections.
Constructs Methylation # Embryos TG CP TG Frequency CP Frequency Penetrance CP, not TG
Lentivirus plasmid No 88 16 0 0.18 0 NA 0
empty
U6; GFP
Lentivirus plasmids No 248 8 0* 0.03 0* 0* 0
nt1266, nt1894
U6; GFP
Lentivirus plasmid No 55 26 5* 0.47 0.09 0.15 1
nt622
U6; GFP
SB Yes 56 32 0 0.57 0 0 0
nt622 scrambled
CpG-free H1; GFP
SB Yes 79 54 0 0.68 0 0 0
nt622
CpG-free H1; GFP
SB No 32 4 0 0.13 0 0 0
Empty
U6; GFP
SB No 108 5 4 0.05 0.04 0.8 0
nt1266, nt1894
U6; GFP
SB No 57 4 3* 0.07 0.05 0.50* 1
nt1266
U6; no GFP
SB Yes 73 12 2 0.16
$ 0.03 0.17
$ 0
nt1266
U6; no GFP
PB No 59 10 1 0.17 0.02 0.10 0
nt622
U6; no GFP
No PBase control
PB; nt622 No 112 52 12 0.46 0.11 0.23 0
nt622
U6; no GFP
PBase
PB No 20 2 1 0.10 0.05 0.50 0
nt622
U6; no GFP
4-5X PBase
*Denotes one or more transgenic embryos showing early embryonic growth arrest prior to palate fusion.
$Three of 24 resorptions were transgenic.
TG, transgenic embryos; CP, cleft palate; Penetrance, number of transgenic embryos with CP.
doi:10.1371/journal.pone.0014375.t002
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strategy.
The nonviral SB and PB transposon systems have the potential
to efficiently generate transient transgenic embryos expressing
gene-specific shRNAs. Since CpG methylation of SB transposons
can improve transposition frequency [28,29], we first used the SssI
methylase-treated CpG-free SB transposons and SB11 mRNA for
transient transgenic experiments (Fig. 3C, Table 2). We achieved
high transgenic efficiency, 57% and 68%, with a control
transposon (pBB114, scrambled nt622 shRNA) and pBB113
(nt622), respectively, accompanied by variable GFP marker
expression (Fig. 4E-H). However, we observed no embryos with
CP upon dissection at E15.5 (Table 2).
Therefore, we altered several variables in an attempt to
improve shRNA and GFP expression. First, we used the U6 Pol
III promoter, which drives shRNA expression with greater
efficiency than the H1 Pol III promoter [30]. We subcloned the
CpG-containing U6-shRNA; CMV-eGFP expression cassette
(1.94 kb) from pLL3.7 into the SB transposon plasmid. GFP
expression is robust when expressed from this cassette in vivo
(Fig. 4A). We did not methylate these transposons before
injection due to the presence of many CpG dinucleotides
(Fig. 3A, data not shown). Transgenic injection of pBB160
(control), pBB161 (nt1266) and pBB162 (nt1894) produced much
lower transgenic efficiencies than with the CpG-free transposons,
(13%, 5% and 5%, respectively), However, the small number of
Figure 4. Transient transgenic RNAi knockdown of Prdm16 in mice recapitulates the recessive csp1 ENU mutant phenotype. A) Strong
GFP expression driven by the CMV-eGFP cassette with plasmid DNA injection of pLL3.7. B) Similarly strong ubiquitous GFP expression visible in some
lentivirus infected transient transgenic Prdm16 RNAi knock down E16.5 embryos. Wild-type (C) and transgenic (D) E16.5 embryos with fused and cleft
palate, respectively, representative of the CP phenotype observed in affected transgenic embryos produced using delivery vehicles reported in this
study. Variable GFP expression pattern observed in transgenic embryos carrying CpG-free SB transposons with the H1-GFP cassette, also
representative of the variability of GFP expression pattern observed in all constructs utilizing a GFP expression cassette (E–H). Insets consist of higher
magnification images taken of head regions from these same embryos. I) Western blot analysis for PRDM16 in nuclear lysates isolated from non-
transgenic wild type (Non-Tg, wt) and transgenic CP E16.5 embryonic heads derived from pronuclear injection of a Prdm16-specific shRNA-expressing
PB transposon. LAMIN B1 expression is provided as a loading control.
doi:10.1371/journal.pone.0014375.g004
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and Table S1).
As CMV-driven GFP expression was variable and often difficult
to visualize; and since we screen all embryos for phenotypic
abnormalities, the utility of the GFP marker in these transposons is
limited. Therefore, we removed the CMV-eGFP expression
cassette to generate a smaller transposon containing only the
U6-shRNA expression cassette (0.56 kb, Fig. 3E). Methylation by
CpG methylases and reduced transposon size address two
variables known to improve SB transposition efficiency [27]
(Largaespada, D.A., personal communication). We performed
multiple transgenic injections to investigate these variables and
observed little difference in outcome (Table 2).
In contrast, utilization of a PB transposon that expresses a
Prdm16-specific shRNA driven by the U6 Pol III promoter proved
much more successful (Table 2 and Table S1). We compared the
transgenic efficiency and phenotypic penetrance achieved utilizing
differing amounts of the PB transposon plasmid DNA and PBase
mRNA. Control experiments with no co-injected PBase mRNA
produced yielded 59 embryos, 10 (17%) of which were transgenic
with 1 (2%) exhibiting CP. Therefore, transgenic efficiency was
within the normal range for a traditional transgenic DNA injection
experiment, and the CP penetrance in transgenic embryos was
10%. The same amount of transposon DNA (,2.0 mg/ml) co-
injected with PBase mRNA (23 mg/ml) dramatically increased
transgenic efficiency (68%), CP embryos (11%) and penetrance
(16%). A substantial increase in PBase mRNA concentration
(92 mg/ml) did not increase these values. On the contrary, we
observed a marked increase in resorptions, decrease in live
embryos and obtained only 10% (2/20) transgenic efficiency with
only 1 affected embryo (5%). A slight reduction in PB transposon
concentration (1.4 mg/ml) co-injected with lower PBase mRNA
concentrations (17 and 23 mg/ml) yielded the most ideal
conditions for these validation studies, increased transgenic
efficiency (32% and 42%) and penetrance (29% and 27%) in 22
and 62 embryos, respectively. On average, use of 1.4–2.0 mg/ml
PB transposon DNA and 17–23 mg/ml PBase mRNA resulted in
46% transgenic efficiency and 23% CP penetrance (Table 2).
To confirm in vivo knockdown of Prdm16 in these embryos,
nuclear protein lysates were isolated from two non-transgenic wild
type and two transgenic CP embryonic heads harvested from a PB
transposon plus PBase mRNA co-injection experiment. Relative
PRDM16 protein levels were determined by Western analysis of
these nuclear fractions to using a rabbit PRDM16-specific
polyclonal antibody (Fig. 4I). Marked reduction of a pair of
protein bands just over 150 kD in size in transgenic embryos with
CP confirmed successful knockdown of Prdm16. Although the
exact nature of these PRDM16 isoforms has not been determined,
specific loss of these protein products has been demonstrated
previously in mutant mice carrying Prdm16 null alleles [21].
Discussion
We chose to pursue transient transgenic RNAi knockdown
during mouse embryogenesis as a means to rapidly validate loss of
function gene mutations, which we have identified as part of an
ENU mutagenesis screen for late embryonic phenotypic anomalies
[15]. Transient transgenic RNAi knockdown has the obvious
advantage of speed over standard homologous recombination in
ES cells for rapid phenotypic validation or candidate gene
screening. Mutant embryos deficient for expression of a gene of
interest can be examined within 2–3 weeks of microinjection.
Resources such as the RNAi Consortium (http://www.broad
institute.org/rnai/trc) and RNAi Codex (http://cancan.cshl.edu/
cgi-bin/Codex/Codex.cgi) increasingly facilitate the selection of
gene-specific siRNA sequences to efficiently knock down gene
function. Even with the selection of high-scoring siRNA target
sequences predicted using bioinformatics tools, one must validate
knockdown efficiency experimentally, which we did using a
luciferase-based in vitro assay [26]. We examined a variety of
vehicles for the delivery of gene-specific shRNAs into mouse
embryos with the aim of producing transgenic mouse embryos
with high frequency, which is crucial to such a screening strategy,
especially given the potential variability of RNAi knockdown
efficiency. All of these methods recapitulated the CP phenotype
observed in Prdm16 mutant mice. Lentivirus-infection and PB
transposon-mediated transgenesis yielded the highest transgenic
efficiency and phenotypic penetrance. Our studies were carried
out using a single gene, Prdm16, to facilitate the comparative
analysis of a multitude of shRNA delivery systems and variables;
extension of these studies to additional candidate genes will be
undertaken to validate the general application of our strategy.
Lentivirus infection has been used effectively to generate stable
transgenic mammalian lines with both constitutive and conditional
expression of transgenes and shRNAs [8,9,10,31,32]. This proved
to be a viable strategy for transient transgenic RNAi knockdown in
mouse embryos using Prdm16-specific shRNAs, although the
specialized training and facilities necessary for working with these
pathogens reduces its attractiveness as a universal tool for these
studies.
The SB system is also a tractable means to perform in vitro and in
vivo transgenic studies of many kinds, including cancer modeling,
gene trapping, generation of transgenic mouse lines and insertional
mutagenesis [33,34,35,36]. Several factors have been shown to
affect the transposition efficiency of SB transposons in vitro. There
is a demonstrated decrease in transposition efficiency that is
directly proportional to transposon size and SB transposase
expression levels over a certain threshold (overproduction
inhibition) [27,37]. CpG methylation of SB transposons and
heterochromatin formation has been shown to increase transposon
excision from the genome and transposition of a plasmid into the
genome, and SB11 transposase shows a high affinity for
heterochromatin [28,29,38]. Methylation of SB transposons has
given rise to very high transgenic efficiency (up to 90%) in mice
(Largaespada, D.A., personal communication). However, the
heterochromatic state can potentially silence promoter activity,
which would mitigate the advantage of increased transposition.
We utilized methylated SB transposons containing CpG-free
shRNA and GFP expression cassettes to attempt to achieve high
transposition/transgenic efficiency without silencing shRNA and
GFP expression. We tested many of the variables above in our SB
transposon injections and achieved little increase in efficiency
(Fig. 3A). We achieved very high transgenic efficiency using CpG-
methylated CpG-free SB expression plasmids, but we did not
obtain any fetuses that recapitulated the csp1 mutant phenotype
(Table S1). We examined transposon size and CpG methylation
status via other CpG-containing SB transposons. Generally, these
variations all resulted in low transgenic efficiency, but yielded a
highly penetrant phenotype. Unfortunately, these attempts to
optimize the SB transposition did not produce the high
transposition/transgenic efficiency coupled with a high phenotypic
penetrance that we desired. Certainly other variables could be
adjusted, such as the amount of transposon DNA and SB11
transposase mRNA injected, in order to improve this system;
however, given our results using the PB transposon system, we did
not pursue further optimization of the SB transposon system.
Recently, a hyperactive SB transposase mutant (SB100X) with
,100-fold increase in transposition efficiency over the first-
Transient Transgenic RNAi
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injection of SB100X transposase and an SB transposon (CAGGS
promoter driving Venus expression) into mouse embryos using
amounts different than in our SB experiments resulted in 37%
transgenic efficiency in newborn mice. Therefore, utilization of the
SB100X transposase in combination with our SB shRNA-
expressing transposons may improve transgenic efficiency to go
along with the high phenotypic penetrance that we observed.
In contrast to our experience using SB transposition, PB
transposon-mediated transgenesis yielded a substantial improve-
ment in transgenic efficiency over traditional plasmid DNA
injections and produced a highly penetrant phenotype. This
result, combined with the observed reasonable phenotypic
penetrance, makes PB transposition an attractive, nonviral
approach to validate positionally-cloned gene mutations and
screen candidate genes. A 4-5-fold increase of PBase mRNA levels
resulted in more resorptions, less live embryos and low transgenic
efficiency. Transposition efficiency is directly dependent upon
increased transposase levels up to a certain threshold level [37];
therefore, our results may reflect this increased transposition
efficiency and a corresponding deleterious effect on viability due to
increased integration events with higher probability of disrupting
essential genes and/or regulatory elements.
Clearly, additional modifications of this system can be
considered. The addition of minimal mammalian insulator
sequences flanking the shRNA expression cassette, such as the
chicken hypersensitive site-4 (cHS4) chromatin insulator, may
mitigate the potential negative effect on shRNA expression of
methylation differences or position effects. One might also
consider additional modifications to this system to more
specifically examine loss of gene function during mouse embryo-
genesis, including gene-specific or temporally-specific RNAi
transgenesis using mouse Pol II RNA polymerase or inducible
promoter sequences.
In summary, we describe the use of transient transgenic RNAi
knockdown to demonstrate the developmental consequences of a
loss of function mutation. We carried out a detailed examination
of the efficacy of lentivirus- and transposable element-based
methods for the delivery of shRNA-expressing transgenes.
Lentivirus infection and PB transgenesis achieved comparably
favorable transgenic efficiency and phenotypic penetrance;
however, the nonviral PB transposon system has significant
advantages since no specialized training, equipment or facilities
are required. Transient transgenic RNAi knockdown can be a
universally tractable, rapid and powerful approach for use in
human and mouse genetic studies to validate positionally cloned
mutations and to screen candidate genes for developmental
phenotypes.
Materials and Methods
shRNA selection and validation
Prdm16-specific shRNAs were chosen using informatics software
that screened the Prdm16 coding sequence for short 19-mer
sequences meeting eight criteria for efficient knockdown of mRNA
expression (score .7) described previously [10,25]. Eight target
sequences showing no homology to other mouse genes were
selected for cloning into the pLenti-Lox3.7 (pLL3.7) lentivirus
plasmid backbone and subsequent in vitro validation of knockdown
efficiency (Table 1) [10]. RNAi knockdown efficiency was
determined experimentally using a previously described luciferase
reporter strategy [26]. RNAi target cDNA sequence contained in a
Gateway Entry vector derived from a Prdm16 EST clone,
GenBank Accession No. CB248179.1 [21] was cloned into the
39 UTR of a modified Firefly luciferase expression plasmid adapted
for use as a destination vector in the Gateway cloning system
(pGL3-DEST) via a LR clonase reaction to make the pGL3-
DEST-Prdm16 (Invitrogen). 100 ng pGL3-DEST-Prdm16,2 5n g
pRL-tk (control Renilla luciferase expression plasmid) and 200 ng
empty pLL3.7 or Prdm16-specific shRNA expression plasmid were
transfected into 293T cells and incubated for 24–36 hours after
which cells were lysed and Firefly and Renilla luciferase activity was
measured as directed using the Dual-Luciferase Reporter Assay
(Promega) in a Veritas Microplate Luminometer (Turner BioSys-
tems). Relative luciferase activity values were calculated as the
ratio of Firefly:Renilla luciferase in each transfected well, and each
transfection was performed in duplicate. RNAi knockdown
efficiency was taken as the ratio of the relative luciferase activity
for the experimental shRNA plasmid over that for the pLL3.7
negative control transfection.
Antibodies and Western blotting. Affinity-purified
PRDM16-specific antiserum raised against an N-terminal
PRDM16 peptide was described previously [21]. Western blots
were performed using established protocols. Nuclear fractions
were isolated from embryonic heads as directed using the NE-PER
Nuclear and Cytoplasmic Extraction kit (Pierce, Rockford, IL).
Nuclear fractions (100 mg) were separated on a 6% polyacrylamide
gel, transferred to PVDF membrane for 2 hours at 600 mA, and
incubated in the presence of PRDM16 N-terminal (1:7500) and
Lamin B1 (1:1000; Abcam) antisera, followed by antibody
detection using the SuperSignal West Femto Maximum
Sensitivity Substrate (Pierce).
Lentiviral plasmid construction
Oligonucleotides containing the sense 19 nt RNAi target
sequence followed by a short loop sequence and the reverse and
complement 19 nt RNAi target sequence and poly-T terminator
sequence. 60 pmoles of each oligonucleotide were annealed to
make dsDNA in Annealing Buffer (100 mM Potassium Acetate,
30 mM Hepes-Potassium Hydroxide, pH 7.4 and 2 mM Magne-
sium Acetate) in a total volume of 50 ml using the following cycling
conditions (95uC, 4 min., 70uC, 10 min. followed by incremental
decrease (0.1uC/min.) to 4uC. Oligonucleotides were 59-phos-
phorylated and designed with 59 and 39 overhangs to allow for
directional cloning into XhoI/HpaI-digested, Calf Intestinal
Phosphatase-treated pLL3.7 plasmid. Ligations were performed
using 60 fmoles of annealed oligonucleotides and linearized
plasmid in a 10 ml reaction volume using the Quick Ligation Kit
(NEB) and transformed into stbl3 chemically competent cells
(Invitrogen). Transformants were screened by colony PCR using
primers that flank the multiple cloning site of pLL3.7 (Table S2).
Sleeping Beauty and PiggyBac transposon construction
Sleeping Beauty. Empty pKT2-HF transposon plasmid
DNA and pT3TS-SB11 transposase expression plasmid were
generously provided by David Largaespada (Univ. of Minn.).
CpG-free plasmids pMOD-ZGFP::sh, pCpG-H1siRNA and
pCpG-mcs (Invivogen) were used to generate CpG-free SB
transposons to avoid gene silencing upon CpG methylation via
SssI methylase (NEB). pKT2-HF and pCpG-H1siRNA plasmids
were digested with EcoRI and HindIII restriction enzymes. The
gel-purified H1siRNA expression cassette fragment was ligated
into the digested and gel-purified pKT2-HF plasmid to make
pKT2-HF-H1siRNA. A CpG-free synthetic GFP coding sequence
was amplified from pMOD-ZGFP::sh plasmid DNA using
oligonucleotides containing BglII (oBB1018) or NheI (oBB1019)
restriction sites at their 59 ends (Table S2). This PCR product and
pCpG-mcs were digested with BglII and NheI restriction enzymes,
Transient Transgenic RNAi
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pKT2-HF-H1siRNA plasmids were each digested with EcoRI,
and the fragment containing the GFP expression cassette was gel-
purified and ligated into the digested pKT2-HF-H1siRNA
plasmid to make pKT2-HF-GFP-H1siRNA. Alternative 59
phosphorylated oligonucleotides with overhangs compatible with
cloning into BbsI sites of the H1siRNA expression cassette
(oBB1022-1033, Table 1) were annealed and ligated into BbsI-
digested pKT-HF-GFP-H1siRNA as described previously for
pLL3.7. In addition, GFP-minus transposons were created by
ligation of annealed oligos into the BbsI sites of pKT2-HF-
H1siRNA.
CpG-containing variations of these SB transposons were
constructed by removing the CMV-eGFP; U6-shRNA expression
cassettes from pLL3.7, pBB30, pBB31 and pBB33 from the
pLL3.7 vector backbone by digestion with XbaI and EcoRI
restriction enzymes. The pKT2-HF transposon plasmid was
digested with SpeI and EcoRI, CIP-treated and ligated to the
XbaI/EcoRI-digested CMV-eGFP; U6-shRNA expression cas-
settes. The empty plasmid backbone is referred to as pKT2-HF-
U6-shRNA-GFP. Later these plasmids were digested with HindIII
to remove the CMV-eGFP expression cassette to make pKT2-HF-
U6-shRNA.
PiggyBac. Empty PB transposon plasmid DNA (pCyL50) and
pCMV-PBase expression plasmids were generously provided by
Pentau Liu (Sanger). The U6-shRNA cassettes from pBB30 were
amplified using primers oBB1336/1337 (504 bp) that contained
AscI or PacI restriction sites at their 59 ends. These PCR products
and pCyL50 plasmid DNA were digested with AscI/PacI and
ligated together to make control and Prdm16-specific shRNA-
expressing PB transposons (Table 1 and Table S2). PvuII digestion
excised the IR-U6-nt622shRNA-IR fragment to be used for
transgenesis. The PB transposase plasmid used as template for in
vitro transcription reactions was constructed as follows. Empty
pT3TS plasmid backbone was obtained by digesting pT3TS-SB11
with BglII [40]. The oligonucleotide linker primers oBB1443 and
oBB1444 (HindIII-NheI-XbaI) designed to have BglII-compatible
59 ends at each end were annealed as described previously and
ligated to BglII-digested, CIP-treated pT3TS to make pT3TS-
linker (pBB231). Colonies were screened for orientation of the
linker by colony PCR using T3/oBB1444. The PB transposase
coding sequence was amplified from pCMV-PBase plasmid DNA
using oBB1445 and oBB1437, which were designed with HindIII
restriction site, Xenopus Globin 59 UTR and BglII, NdeI, SacII
and NheI restriction sites or an SpeI restriction site at their 59
ends, respectively. This PCR product and pBB231 plasmid DNA
were digested with HindIII/SpeI and ligated together to make
pT3TS-PBase (pBB232).
Linearized and gel purified (Qiagen) pT3TS-SB11 (BamHI) or
pT3TS-PBase (XbaI) plasmids were used as template to make 59-
capped SB11 or PBase mRNA, respectively, using the mMessage
mMachine High Yield Capped mRNA T3 Transcription Kit
(Ambion). mRNA was purified using NucAway Spin columns
(Ambion). After determining RNA concentration, samples were
aliquoted in 5 ml volumes and stored at 280uC.
Transgenic mice
Prdm16 shRNA containing SB and PB transposon plasmids were
digested with PvuII (SB) or PvuII/BspHI (PB) to linearize or
remove the plasmid backbone, respectively. Transposon fragments
were purified using either the UltraClean GelSpin DNA
purification kit (Mol Bio, Carlsbad, CA) or electroelution followed
by concentration using the WizardH DNA Clean-Up System
(Promega). Transgenic mice were produced by transgenic
injection of each shRNA-expressing transposon plasmid construct
along with in vitro transcribed 59-capped SB11 or PB transposase
mRNA into the pronuclei of fertilized eggs [41]. For SB
transposon injections plasmid DNA was diluted to 4 mg/ml in
injection buffer (5 mM Tris-Cl pH 7.5, 0.1 mM EDTA), and SB
mRNA is added to a concentration of 10 mg/ml, aliquoted and
stored at 270uC about 2–3 days before injection. For PB
transposon injections plasmid DNA was diluted to 1.4–2.0 mg/
ml of DNA along with 17, 23, 92 mg/ml or no PBase mRNA in
injection buffer. CD-1 females were used as recipients for injected
embryos.
All mice were housed in a 12-h light, 12-h dark cycle with
unlimited access to tap water and Purina 5008 or 5020 chows. All
procedures using mice were approved by the University of
Michigan Committee on Use and Care of Animals, and all
experiments were conducted in accordance with the principles and
procedures outlined in the NIH Guidelines for the Care and Use
of Experimental Animals.
Foster mother mice were euthanized on E15.5, E16.5 or E17.5
to screen potential transgenic embryos for cleft palate. For each
embryo assayed the limbs and tail were collected for genotyping,
the head was fixed in 3.7% Formaldehyde in Phosphate Buffered
Saline, pH 7 overnight at 4uC, and, for select embryos, the body
was stored in RNA Later (Ambion) at 220 C. After fixing, heads
were washed and dehydrated through a graded ethanol series to
70% ethanol and stored at 220uC. Genotyping samples were
processed as described previously [42]. All embryos were
genotyped for the presence of a transgene by PCR using
oligonucleotide primers provided in Table S2.
Supporting Information
Table S1 Detailed summary of transgenic RNAi injections.
Found at: doi:10.1371/journal.pone.0014375.s001 (0.11 MB
DOC)
Table S2 Additional oligonucleotide primers.
Found at: doi:10.1371/journal.pone.0014375.s002 (0.06 MB
DOC)
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